{"id":"autologous-menstrual-blood-stem-cells","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Allergic reaction"}]},"_chembl":{"chemblId":"CHEMBL5315099","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Menstrual blood contains a population of stem cells (endometrial stem cells) with high proliferative capacity and immunomodulatory properties. When isolated and expanded ex vivo, these autologous cells can differentiate into multiple cell types and secrete anti-inflammatory cytokines, potentially promoting tissue repair and reducing pathological inflammation in target tissues. The autologous nature minimizes immunological rejection.","oneSentence":"Autologous menstrual blood-derived stem cells are harvested from a patient's own menstrual fluid and reinfused to promote tissue regeneration and reduce inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:00.722Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asherman's syndrome (intrauterine adhesions)"},{"name":"Premature ovarian failure / primary ovarian insufficiency"}]},"trialDetails":[{"nctId":"NCT06896747","phase":"PHASE1, PHASE2","title":"Evaluating Mechanically Engineered Stem Cell Exosomes for Treating Endometrial Injury: A Clinical Study","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2025-02-21","conditions":"Thin Endometrial Lining, Female Infertility, Intrauterine Adhesions","enrollment":90},{"nctId":"NCT05703308","phase":"PHASE3","title":"Menstrual Blood Stem Cells in Poor Ovarian Responders","status":"COMPLETED","sponsor":"Avicenna Research Institute","startDate":"2020-06-21","conditions":"Poor Ovarian Response, Infertility, Female","enrollment":180}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Autologous Menstrual Blood Stem Cells","genericName":"Autologous Menstrual Blood Stem Cells","companyName":"Avicenna Research Institute","companyId":"avicenna-research-institute","modality":"Biologic","firstApprovalDate":"","aiSummary":"Autologous menstrual blood-derived stem cells are harvested from a patient's own menstrual fluid and reinfused to promote tissue regeneration and reduce inflammation. Used for Asherman's syndrome (intrauterine adhesions), Premature ovarian failure / primary ovarian insufficiency.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}